Zealand Pharma announces first patient dosed in Phase 2 trial with long-acting GLP-1/glucagon dual agonist in obesity/diabetes
24. Juni 2020 02:55 ET
|
Zealand Pharma
Company announcement – No. 38 / 2020 Zealand Pharma announces first patient dosed in Phase 2 trial with long-acting GLP-1/glucagon dual agonist in obesity/diabetes The 410-patient...